Análise imunohistoquímica dos proteoglicanossindecan, decorin e biglican na próstata normal e hiperplásica

• Autor(a) principal: Ribeiro, Bruno Leonardo Marroig de Freitas
• Data de Publicação: 2011
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Biblioteca Digital de Teses e Dissertações da UERJ
• Texto Completo: http://www.bdtd.uerj.br/handle/1/12363
• topic: Prostate; Hyperplasia; Proteoglycans; Immunohistochemistry; Syndecan-1; Decorin; Biglycan; Próstata; Hiperplasia; Proteoglicanos; Imunohistoquímica; Sindecan-1; Decorin; Biglican; Próstata Doenças; Matriz extracelular; Próstata hipertrofia; Proteoglicanas; CNPQ::CIENCIAS DA SAUDE::MEDICINA

The cellular mechanisms involved in benign prostatic hyperplasia (BPH) are not well understood, and little is known about how proteoglycans are affected. Here we investigated the protein expression of stromal and cell surface proteoglycans in BPH. BPH samples were colected from open prostatectomy and transurethral resection of the prostate (TURP), while controls consisted of the transitional zone of normal prostates from young adults. We used primary antibodies against the proteoglycans syndecan-1, biglycan, and decorin. Immunolabeling was evaluated by determining the relative area of staining, or by using a score for staining intensity. The results showed that, in controls, syndecan-1 was mostly negative. In BPH, however, the labeling of this proteoglycan was intense and located mainly in acinar basal cells, but could extended into the secretory cells. As there were no differences in samples from open prostatectomy and TURP, these groups were combined into a BPH group. Syndecan-1 labeling area in the epithelium of BPH samples was nine times greater than that of controls (p<0,001), and there were no significant correlations between syndecan-1 labeling in BPH and prostate volume, PSA, or patient s age. Biglycan and decorin labeling were in the stroma exclusively, in control and BPH samples, and there were no significant differences in extent and intensity of the staining between these two groups. In conclusion, syndecan-1 immunolabeling in BPH is prominent and is located in the glandular epithelium exclusively, but intensity does not correlate with prostate size or PSA. Decorin and biglycan labeling, however, were unchanged in BPH.